SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference, Boston, MA Format – Fireside chat and one-on-one investor meetingsDate a ...

Core Insights - AnaptysBio, Inc. is focused on developing innovative immunology therapeutics, with key upcoming clinical data releases for its drug candidates ANB032 and rosnilimab in atopic dermatitis and rheumatoid arthritis, respectively [1][2][3][4] Clinical Development Updates - Top-line Phase 2b data for ANB032, a BTLA agonist, is expected in December 2024, with approximately 200 patients enrolled in a placebo-controlled trial [3] - Top-line Phase 2b data for rosnilimab, a PD-1 agonist, is anticipated in February 2025, following the completion of enrollment of around 420 patients [4] - A Phase 1 trial for ANB033, an anti-CD122 antagonist, has been initiated in healthy volunteers, with further indications expected in 2025 [5] Financial Performance - As of September 30, 2024, the company reported cash and investments totaling $458.0 million, an increase from $417.9 million at the end of 2023, primarily due to a $100.0 million offering and $50.0 million from royalty monetization [7] - Collaboration revenue for Q3 2024 was $30.0 million, significantly up from $3.3 million in Q3 2023, driven by a commercial milestone from Jemperli sales [7] - Research and development expenses rose to $42.2 million for Q3 2024, compared to $30.9 million in Q3 2023, reflecting increased development costs for key drug candidates [7] Pipeline Overview - The company has multiple programs in clinical development, including ANB032 for atopic dermatitis, rosnilimab for rheumatoid arthritis and ulcerative colitis, and ANB101, a BDCA2 modulator, which is set to enter Phase 1 trials in Q1 2025 [9] - AnaptysBio also has legacy cytokine antagonist programs available for out-licensing, including imsidolimab, which has completed Phase 3 trials for generalized pustular psoriasis [5][9]

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences: 2024 Wells Fargo Healthcare Conference, Boston, MA Format – Fireside chat and one-on-one investor meetingsDate and Time – Thursda ...

Core Viewpoint - AnaptysBio is experiencing a positive trend in its stock price, driven by investor interest following a favorable research note and upcoming clinical trial results [1][2]. Group 1: Stock Performance - AnaptysBio's share price increased by nearly 10% week to date as of Friday before market open [1]. - Guggenheim analyst Yatin Suneja reiterated a buy rating on AnaptysBio, maintaining a price target of $75 per share, which is more than double the stock's latest closing price [2]. Group 2: Clinical Developments - A phase 2 clinical trial for AnaptysBio's investigational drug for atopic dermatitis is expected to produce results in December, with company officials expressing confidence in the outcome [2]. - The positive outlook is supported by the company's engagement with investors and the anticipation of clinical readouts [1][2]. Group 3: Financial Backing - AnaptysBio announced a $100 million stock offering that included participation from global pharmaceutical company Sanofi, indicating strong confidence in AnaptysBio's pipeline [2].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. (Exact name of registrant as specified in its charter) Delaware 20-3828755 (State or other jurisdiction of incorpo ...

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update • Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist • Top-line data accelerated and now anticipated in Q1 2025 for Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist • Top-line data now anticipated in Q1 2026 for Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab • IND accepte ...

Wall Street expects a year-over-year increase in earnings on higher revenues when AnaptysBio, Inc. (ANAB) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock ma ...

Loading...Loading...HC Wainwright analyst initiated coverage on AnaptysBio Inc ANAB, a clinical-stage biotechnology company focused on delivering immunology therapeutics.AnaptysBio has a pipeline of checkpoint agonists, including rosnilimab, a PD-1 agonist in development for rheumatoid arthritis (RA) and ulcerative colitis (UC), and ANB032, a B and T cell lymphocyte attenuator (BTLA) agonist in development for atopic dermatitis (AD).In Phase 1, rosnilimab showed a 90% reduction of T cell proliferation, infl ...

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.64 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $1.58 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.49%. A quarter ago, it was expected that this company would post a loss of $1.74 per share when it actually produced a loss of $1.59, delivering a surprise of 8.62%.Over the last four quarters, the company has surpasse ...

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This section presents the unaudited consolidated financial statements, management's discussion, market risk, and internal controls [Item 1. Consolidated Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Consolidated%20Financial%20Statements%20(unaudited)) The company reported a net loss with decreased total assets, a significant royalty liability, and a subsequent royalty monetization amendment [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) This section presents the company's financial position, highlighting changes in assets, liabilities, and equity Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Cash and cash equivalents | $53,695 | $35,965 | | Short-term investments | $300,970 | $354,939 | | **Total Assets** | **$405,835** | **$452,389** | | Total current liabilities | $32,298 | $37,442 | | Liability related to sale of future royalties | $310,184 | $310,807 | | **Total Liabilities** | **$358,057** | **$364,286** | | **Total Stockholders' Equity** | **$47,778** | **$88,103** | [Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) This section details the company's financial performance, including revenue, expenses, and net loss Consolidated Statements of Operations (Unaudited, in thousands, except per share data) | Metric | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Collaboration revenue | $7,179 | $1,374 | | Research and development | $37,042 | $34,957 | | General and administrative | $12,338 | $10,818 | | Loss from operations | ($42,201) | ($44,401) | | Net loss | ($43,936) | ($44,255) | | Net loss per common share | ($1.64) | ($1.58) | [Consolidated Statements of Cash Flows](index=8&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) This section outlines the company's cash inflows and outflows from operating, investing, and financing activities Consolidated Statements of Cash Flows (Unaudited, in thousands) | Activity | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Net cash used in operating activities | ($37,253) | ($24,568) | | Net cash provided by investing activities | $68,616 | $85,396 | | Net cash used in financing activities | ($13,633) | ($37,574) | | **Net increase in cash and cash equivalents** | **$17,730** | **$23,254** | [Notes to the Unaudited Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20the%20Unaudited%20Consolidated%20Financial%20Statements) This section provides detailed explanations and additional information supporting the consolidated financial statements - The company is a clinical-stage biotechnology firm developing immune cell modulating antibodies, with revenue from GSK collaboration milestones and royalties[16](index=16&type=chunk) - Collaboration revenue from GSK's Jemperli and Zejula sales significantly increased to **$7.2 million** in Q1 2024, though this revenue is non-cash due to royalty monetization agreements[30](index=30&type=chunk) - A subsequent amendment to the Jemperli Royalty Monetization Agreement provided an additional **$50.0 million** upfront cash in May 2024[70](index=70&type=chunk) - As of March 31, 2024, the company held liabilities of **$278.2 million** for Jemperli and **$32.0 million** for Zejula royalty sales[37](index=37&type=chunk)[39](index=39&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=27&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section discusses the company's pipeline progress, financial performance drivers, and liquidity position Wholly Owned Product Candidate Pipeline Status | Program | Indication | Status | Anticipated Milestone | | :--- | :--- | :--- | :--- | | ANB032 (BTLA agonist) | Atopic Dermatitis | Phase 2b | Top-line data YE 2024 | | Rosnilimab (PD-1 agonist) | Rheumatoid Arthritis | Phase 2b | Top-line data mid-2025 | | Rosnilimab (PD-1 agonist) | Ulcerative Colitis | Phase 2 | Top-line data H1 2026 | | ANB033 (CD122 antagonist) | Inflammatory Diseases | Preclinical | IND submission Q2 2024 | | ANB101 (BDCA2 modulator) | Inflammatory Diseases | Preclinical | IND submission H2 2024 | | Imsidolimab (IL-36R antagonist) | GPP | Phase 3 Completed | Out-license in 2024 | R&D Expense Breakdown (in thousands) | Program | Q1 2024 | Q1 2023 | Change | | :--- | :--- | :--- | :--- | | Rosnilimab | $10,038 | $2,605 | $7,433 | | ANB032 | $4,866 | $2,536 | $2,330 | | Imsidolimab | $4,496 | $15,463 | ($10,967) | | **Total R&D Costs** | **$37,042** | **$34,957** | **$2,085** | - Collaboration revenue increased to **$7.2 million** in Q1 2024 due to higher GSK product sales, which is non-cash and reduces royalty monetization liabilities[98](index=98&type=chunk) - The company's cash, cash equivalents, and investments totaled **$370.1 million** at Q1 2024, projected to fund operations for at least the next twelve months[105](index=105&type=chunk)[107](index=107&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=38&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company reports no material changes to its market risk profile since its most recent annual report - No material changes occurred in the company's market risk profile as of March 31, 2024, compared to its latest Form 10-K disclosures[115](index=115&type=chunk) [Item 4. Controls and Procedures](index=38&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls were effective, with no material changes to internal control over financial reporting during the quarter - The CEO and CFO affirmed the effectiveness of the company's disclosure controls and procedures[116](index=116&type=chunk) - No material changes in internal control over financial reporting occurred during the quarter[117](index=117&type=chunk) [PART II. OTHER INFORMATION](index=39&type=section&id=PART%20II.%20OTHER%20INFORMATION) This section covers legal proceedings, risk factors, equity sales, other information, and exhibits [Item 1. Legal Proceedings](index=39&type=section&id=Item%201.%20Legal%20Proceedings) The company may face ordinary course legal proceedings but reports no specific material litigation - The company may engage in ordinary course legal proceedings, but no specific material proceedings are currently reported[119](index=119&type=chunk) [Item 1A. Risk Factors](index=39&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks related to product development, financial sustainability, operational dependencies, and market competition - Key risks include potential failure or delays in developing early-stage product candidates, as initial clinical trial results may not be indicative of later trials[121](index=121&type=chunk)[123](index=123&type=chunk) - The company has a history of operational losses, lacks approved products, and requires additional capital that may not be available on favorable terms[122](index=122&type=chunk)[144](index=144&type=chunk)[147](index=147&type=chunk) - The business relies heavily on its GSK collaboration and third-party manufacturers, posing risks to partnerships, supply chain, and production[122](index=122&type=chunk)[150](index=150&type=chunk) [Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities](index=75&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities,%20Use%20of%20Proceeds%20and%20Issuer%20Purchases%20of%20Equity%20Securities) This section is reported as not applicable for the current period - This section is not applicable for the reporting period[214](index=214&type=chunk) [Item 5. Other Information](index=77&type=section&id=Item%205.%20Other%20Information) Two directors established Rule 10b5-1 trading plans for common stock sales in March 2024 - In March 2024, directors Hollings C. Renton and Dennis M. Fenton established Rule 10b5-1 trading plans for the sale of **56,121** and **4,965** shares, respectively[217](index=217&type=chunk) [Item 6. Exhibits](index=77&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including a license agreement amendment and officer certifications - The report includes an amendment to the license agreement with Centessa Pharmaceuticals (UK) Limited as an exhibit[219](index=219&type=chunk)